Ausun Pharm: Has repurchased a total of 5.2012 million shares, amounting to 50.006 million yuanZhitong·Nov 3, 2025 at 01:54 AM603229+1.50%
Ausun Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 207 million yuan, a year-on-year decrease of 9.59%Zhitong·Oct 30, 2025 at 10:20 AM603229+1.50%
Ausun Pharm: Imatinib Mesylate Tablets Obtained Drug Registration CertificateZhitong·Sep 16, 2025 at 03:15 AM603229+1.50%
Ausun Pharm released its semi-annual performance report, with a net profit attributable to the parent company of 169 million yuan, a year-on-year decrease of 5.83%Zhitong·Aug 28, 2025 at 02:50 AM603229+1.50%
Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit downZhitong·Aug 3, 2025 at 10:11 PM000813+0.92%688302+2.44%
CRO concept stocks fluctuated lower in early trading, Ausun Pharm fell over 8%Zhitong·Aug 3, 2025 at 08:44 PM603127+3.72%061270.00%
Midday Review: The ChiNext Index performed strongly, rising nearly 1%, with the pharmaceutical sector showing broad strengthZhitong·Jul 28, 2025 at 10:33 PM300725+2.29%603229+1.50%
Ausun Pharm released its first-quarter performance, with a net profit attributable to the parent company of 119 million yuan, a year-on-year increase of 5.97%Zhitong·Apr 29, 2025 at 08:41 AM603229+1.50%
Ausun Pharm: The raw material drug of hydrochloride of lobeliaine has obtained the European CEP certificateZhitong·Apr 3, 2025 at 03:01 AM603229+1.50%
Ausun Pharm has obtained special loan support for stock repurchase of no more than 90 million yuanZhitong·Feb 11, 2025 at 04:12 AM603229+1.50%
Ausun Pharm plans to spend between 50 million and 100 million yuan to repurchase sharesZhitong·Jan 26, 2025 at 02:17 AM603229+1.50%
Ausun Pharm's controlling shareholder proposed to spend between 50 million to 100 million yuan to repurchase the company's sharesZhitong·Jan 14, 2025 at 03:14 AM603229+1.50%
The pharmaceutical sector retraced, Ausun Pharm hit the limit downZhitong·Jan 6, 2025 at 07:42 PM000952+2.02%603229+1.50%
Ausun Pharm: Cooperative product Imatinib Mesylate Tablets obtained overseas listing approvalZhitong·Dec 20, 2024 at 01:39 AM603229+1.50%
